awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33814908-201DE715-AC09-4BDD-8FE9-3A29FF62A4F8
Q33814908-201DE715-AC09-4BDD-8FE9-3A29FF62A4F8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33814908-201DE715-AC09-4BDD-8FE9-3A29FF62A4F8
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016
P2860
Q33814908-201DE715-AC09-4BDD-8FE9-3A29FF62A4F8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33814908-201DE715-AC09-4BDD-8FE9-3A29FF62A4F8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1008470f6e0a5fc318394a6ed0ad7706703a70f0
P2860
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.